MARKET

VIRX

VIRX

Viracta Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.51
+0.12
+1.43%
After Hours: 8.51 0 0.00% 16:00 09/21 EDT
OPEN
8.47
PREV CLOSE
8.39
HIGH
8.81
LOW
8.23
VOLUME
134.25K
TURNOVER
--
52 WEEK HIGH
24.80
52 WEEK LOW
3.920
MARKET CAP
316.80M
P/E (TTM)
-1.1473
1D
5D
1M
3M
1Y
5Y
Viracta Therapeutics to Present at Upcoming Investor Conferences in September
/PRNewswire/ --  Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, todayannounced that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23 Annual ...
PR Newswire - PRF · 09/07 12:00
Palo Alto Investors LP Buys Syndax Pharmaceuticals Inc, Viracta Therapeutics Inc, Sells Staar ...
GuruFocus News · 08/24 17:38
BRIEF-Salubris Pharma Ditches Plan To Obtain Right In Viracta's Nanatinostat In China
reuters.com · 08/23 12:41
BRIEF-Viracta Therapeutics Reacquires Exclusive Development And Commercialization Rights For Its All-Oral Combination Therapy In China
reuters.com · 08/23 12:09
Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China
/PRNewswire/ --  Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in...
PR Newswire - PRF · 08/23 12:00
Viracta Therapeutics Reacquires Exclusive Rights to Combination Therapy Candidate for Lymphoma in China
MT Newswires · 08/23 10:07
Viracta Therapeutics-Sponsored Study Titled 'An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)' Posted To ClinicalTrials.Gov
https://clinicaltrials.gov/ct2/show/NCT05011058
Benzinga · 08/18 13:38
Viracta Therapeutics Q2 EPS $(0.25) Up From $(15.52) YoY
Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.25) per share. This is a 98.39 percent increase over losses of $(15.52) per share from the same period last year.
Benzinga · 08/12 12:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIRX. Analyze the recent business situations of Viracta Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIRX stock price target is 27.85 with a high estimate of 45.00 and a low estimate of 5.25.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 19.03M
% Owned: 51.12%
Shares Outstanding: 37.23M
TypeInstitutionsShares
Increased
11
4.40M
New
25
1.63M
Decreased
13
1.22M
Sold Out
14
1.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
President/Chief Executive Officer
Ivor Royston
Chief Financial Officer/Chief Operating Officer/Secretary/IR Contact Officer
Daniel Chevallard
Executive Vice President/Chief Scientific Officer
Judith Fox
Other
Lisa Rojkjaer
Independent Director
Jane Barlow
Independent Director
Flavia Borellini
Independent Director
Nicole Onetto
Independent Director
Stephen Rubino
Independent Director
Barry Simon
No Data
About VIRX
Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).

Webull offers kinds of Viracta Therapeutics Inc stock information, including NASDAQ:VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.